Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 60

1.

Induction of Nrf2 and xCT are involved in the action of the neuroprotective antibiotic ceftriaxone in vitro.

Lewerenz J, Albrecht P, Tien ML, Henke N, Karumbayaram S, Kornblum HI, Wiedau-Pazos M, Schubert D, Maher P, Methner A.

J Neurochem. 2009 Oct;111(2):332-43. doi: 10.1111/j.1471-4159.2009.06347.x. Epub 2009 Aug 18.

PMID:
19694903
[PubMed - indexed for MEDLINE]
2.

Mechanisms of oxidative glutamate toxicity: the glutamate/cystine antiporter system xc- as a neuroprotective drug target.

Albrecht P, Lewerenz J, Dittmer S, Noack R, Maher P, Methner A.

CNS Neurol Disord Drug Targets. 2010 Jul;9(3):373-82. Review.

PMID:
20053169
[PubMed - indexed for MEDLINE]
3.

Regulation of xCT expression and system x (c) (-) function in neuronal cells.

Lewerenz J, Maher P, Methner A.

Amino Acids. 2012 Jan;42(1):171-9. doi: 10.1007/s00726-011-0862-x. Epub 2011 Mar 3. Review.

PMID:
21369940
[PubMed - indexed for MEDLINE]
4.

Nrf2 and antioxidant defense against CYP2E1 toxicity.

Cederbaum A.

Expert Opin Drug Metab Toxicol. 2009 Oct;5(10):1223-44. doi: 10.1517/17425250903143769. Review.

PMID:
19671018
[PubMed - indexed for MEDLINE]
5.

The oxidative stress-inducible cystine/glutamate antiporter, system x (c) (-) : cystine supplier and beyond.

Conrad M, Sato H.

Amino Acids. 2012 Jan;42(1):231-46. doi: 10.1007/s00726-011-0867-5. Epub 2011 Mar 16. Review.

PMID:
21409388
[PubMed - indexed for MEDLINE]
6.

Importance of astrocytic inactivation of synaptically released glutamate for cell survival in the central nervous system--are astrocytes vulnerable to low intracellular glutamate concentrations?

Had-Aissouni L, Ré DB, Nieoullon A, Kerkerian-Le Goff L.

J Physiol Paris. 2002 Apr-Jun;96(3-4):317-22. Review.

PMID:
12445912
[PubMed - indexed for MEDLINE]
7.

Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals.

Surh YJ, Kundu JK, Na HK.

Planta Med. 2008 Oct;74(13):1526-39. doi: 10.1055/s-0028-1088302. Epub 2008 Oct 20. Review.

PMID:
18937164
[PubMed - indexed for MEDLINE]
8.

[Molecular mechanism of neuroprotective drugs against oxidative stress-induced neuronal cell death].

Hara H.

Yakugaku Zasshi. 2007 Aug;127(8):1199-205. Review. Japanese.

PMID:
17666870
[PubMed - indexed for MEDLINE]
Free Article
9.

The Nrf2-ARE cytoprotective pathway in astrocytes.

Vargas MR, Johnson JA.

Expert Rev Mol Med. 2009 Jun 3;11:e17. doi: 10.1017/S1462399409001094. Review.

PMID:
19490732
[PubMed - indexed for MEDLINE]
10.

Late appearance of glutamate transporter defects in a murine model of ALS-parkinsonism dementia complex.

Wilson JM, Shaw CA.

Neurochem Int. 2007 Jun;50(7-8):1067-77. Epub 2006 Nov 13. Review.

PMID:
17095122
[PubMed - indexed for MEDLINE]
11.

The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities.

Lewerenz J, Hewett SJ, Huang Y, Lambros M, Gout PW, Kalivas PW, Massie A, Smolders I, Methner A, Pergande M, Smith SB, Ganapathy V, Maher P.

Antioxid Redox Signal. 2013 Feb 10;18(5):522-55. doi: 10.1089/ars.2011.4391. Epub 2012 Aug 3. Review.

PMID:
22667998
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics.

Kim K, Lee SG, Kegelman TP, Su ZZ, Das SK, Dash R, Dasgupta S, Barral PM, Hedvat M, Diaz P, Reed JC, Stebbins JL, Pellecchia M, Sarkar D, Fisher PB.

J Cell Physiol. 2011 Oct;226(10):2484-93. doi: 10.1002/jcp.22609. Review.

PMID:
21792905
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

The transcription factor Nrf2 as a new therapeutic target in Parkinson's disease.

Cuadrado A, Moreno-Murciano P, Pedraza-Chaverri J.

Expert Opin Ther Targets. 2009 Mar;13(3):319-29. doi: 10.1517/13543780802716501 . Review.

PMID:
19236154
[PubMed - indexed for MEDLINE]
14.

The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration.

Johnson JA, Johnson DA, Kraft AD, Calkins MJ, Jakel RJ, Vargas MR, Chen PC.

Ann N Y Acad Sci. 2008 Dec;1147:61-9. doi: 10.1196/annals.1427.036. Review.

PMID:
19076431
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

[Cerebral oxidative stress: are astrocytes vulnerable to low intracellular glutamate concentrations? Consequences for neuronal viability].

Ré DB, Nafia I, Nieoullon A, Le Goff LK, Had-Aissouni L.

Ann Fr Anesth Reanim. 2005 May;24(5):502-9. Review. French.

PMID:
15885966
[PubMed - indexed for MEDLINE]
16.

Regulation of neuronal glutathione synthesis.

Aoyama K, Watabe M, Nakaki T.

J Pharmacol Sci. 2008 Nov;108(3):227-38. Epub 2008 Nov 13. Review.

PMID:
19008644
[PubMed - indexed for MEDLINE]
Free Article
17.

Thinking outside the cleft to understand synaptic activity: contribution of the cystine-glutamate antiporter (System xc-) to normal and pathological glutamatergic signaling.

Bridges R, Lutgen V, Lobner D, Baker DA.

Pharmacol Rev. 2012 Jul;64(3):780-802. doi: 10.1124/pr.110.003889. Review.

PMID:
22759795
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

[Multiple functions of glutamate transporter EAAC1 in motor neurons].

Kiyama H, Kiryu-Seo S.

Brain Nerve. 2007 Dec;59(12):1325-32. Review. Japanese.

PMID:
18095481
[PubMed - indexed for MEDLINE]
19.

Is erythropoietin a potential therapy for amyotrophic lateral sclerosis?

Butsch PO, Cudkowicz ME.

Exp Neurol. 2007 Jul;206(1):11-5. Epub 2007 Apr 11. Review. No abstract available.

PMID:
17498699
[PubMed - indexed for MEDLINE]
20.

The x(c)- cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases.

Lo M, Wang YZ, Gout PW.

J Cell Physiol. 2008 Jun;215(3):593-602. doi: 10.1002/jcp.21366. Review.

PMID:
18181196
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk